Patients with advanced-stage iNHL, including follicular lymphoma and marginal zone lymphoma, frequently relapse with standard treatment. Axi-cel had positive results in relapsed LBCL [3] and is therefore investigated as potential therapy in iNHL. Dr Caron Jacobson (Dana Farber Cancer Institute, Massachusetts, USA) presented the primary analysis of ZUMA-5 (NCT03105336), a multicentre, single-arm, phase 2 study of axi-cel in patients with R/R iNHL after ≥2 lines of therapy [1].
Axi-cel resulted in high rates of durable responses, with an overall response rate of 92% in patients with iNHL (94% in follicular lymphoma) and a complete response rate of 76% (80% in follicular lymphoma). “Although longer follow-up is needed, these responses appeared to be durable,” Dr Jacobson said. Response rates were consistent among patients with high-risk features. With a median follow-up of 17.5 months, 64% of patients with follicular lymphoma remained in response and responses were ongoing in 78% of patients who achieved a complete response.
The safety profile was manageable and appeared favourable in patients with follicular lymphoma, consistent with that previously reported in LBCL [4]. A lower incidence of grade ≥3 neurologic events was observed in patients with follicular lymphoma compared with marginal zone lymphoma. No grade 5 neurologic events occurred; one event of grade 5 cytokine-release syndrome occurred [1]. Based on the safety profile observed, an evaluation of the potential for outpatient treatment with axi-cel in iNHL is planned.
- Jacobson C, et al. Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). 62nd ASH Annual Meeting, 5-8 December 2020. Abstract 700.
- Locke FL, et al. Lancet Oncol. 2019;20:31-42.
- Jacobson C, et al. Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). 62nd ASH Annual Meeting, 5-8 December 2020. Abstract 1187.
- Neelapu SS, et al. N Engl J Med. 2017;377:2531-44.
Posted on
Previous Article
« Additional HFrEF education and patient-engagement tools Next Article
“Strongly consider an SGLT2-inhibitor in most T2DM patients” »
« Additional HFrEF education and patient-engagement tools Next Article
“Strongly consider an SGLT2-inhibitor in most T2DM patients” »
Table of Contents: ASH 2020
Featured articles
COVID-19
More complicated course of COVID-19 in leukaemia patients
Older age and imatinib treatment associated with COVID-19 mortality in CML
Allogeneic SARS-CoV-2-specific T cells to treat COVID-19
More severe COVID-19 outcomes for patients with haematologic malignancies
Acute Lymphoblastic Leukaemia
Improved outcomes, but still substantial part experiences relapses
Strong correlation between peripheral blood and bone marrow NGS MRD
Encouraging outcomes after autoHCT in patients with ALL
Acute Myeloid Leukaemia
Prognostic validity of AML composite model in predicting mortality
Venetoclax plus hypomethylating agents in favourable-risk AML
Encouraging clinical activity of decitabine plus ipilimumab in R/R or secondary MDS/AML
AML patients with specific mutations are unlikely to achieve MRD
Comparable outcomes with gilteritinib or quizartinib in R/R AML
First-in-class macrophage immune checkpoint inhibitor in AML
Bispecific DART® as salvage therapy for primary induction failure and early relapse
Gilteritinib in R/R AML patients priorly treated with midostaurin or sorafenib
Addition of venetoclax provides an effective, lower-intensity regimen
Chronic Leukaemia
Bosutinib effective and well tolerated in newly diagnosed CP-CML
Efficacy and safety of ponatinib in patients with CP-CML who failed second-generation TKIs
First-in-class STAMP inhibitor versus bosutinib in resistant or intolerant CML
PFS and ORR benefits of first-line ibrutinib-based treatment in CLL
Multiple Myeloma
Validation of MY-RADS response assessment category criteria
High symptom burden in transplant-ineligible patients with newly diagnosed MM
Added value of ixazomib to lenalidomide plus dexamethasone in transplant-ineligible newly diagnosed MM
Survival of transplant-eligible newly diagnosed MM in FORTE trial
Better survival with upfront autoSCT versus bortezomib-based intensification
Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM
Melflufen well tolerated with encouraging activity in heavily pretreated R/R MM
Initial data of FcRH5/CD3 T-cell-engaging bispecific antibody
Lymphoma
CD58 aberrations limit durable responses to CD19 CAR T-cell therapy
Anti-CD19 CAR T-cell therapy in relapsed/refractory indolent NHL
Myeloproliferative Neoplasms
MPN disease burden, quality of life, and treatment patterns
Interventions in JAK/STAT signalling pathway
Novel, orally available inhibitor of BCL-XL/BCL-2
New insights into genetics of MPN
Immune Thrombocytopenia
Mycophenolate efficacious and tolerable, even in elderly patients
First-in-class antibody sutimlimab selectively inhibits classical complement pathway
BTK inhibition provides clinically active and durable platelet response
Haemophilia, Sickle Cell Disease, Thalassaemia
First results from gene therapy trial in haemophilia B
Impact of haemophilia on children and their caregivers
Promising CRISPR gene editing results in β-thalassaemia and sickle cell disease
Erythroid maturation agent in patients with β-thalassaemia requiring regular RBC transfusions
Related Articles
February 18, 2021
Initial data of FcRH5/CD3 T-cell-engaging bispecific antibody
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com